본문 바로가기 주메뉴 바로가기
  • HOME
  • R&D
  • GC Cell R&D Center

GC Cell R&D Center

GC Cell laboratory is focused on the development of anti-cancer immune cell therapy with non-clinical and clinical study.
CAR-T cell as a main pipeline will provide solutions for the treatment of solid tumors. The CAR-T cell targets mesothelin (MSLN)which is overexpressed in solid tumors such as ovarian, pancreatic, and lung cancer, and kills the cancer cells.
GC Cell laboratory is undergoing the autologous/allogeneic CAR-CIK cell therapy for treatment of various cancers via MSLN targeting and MHC-non restrict tumor killing.
GC Cell laboratory will lead the anti-cancer immune cell therapy field through innovative strategies, professionals, and global R&D network.





GC Cell
R&D Center
Immunotherapy
  • Phase Ⅲ clinical Trials in place for hepatocellular
    carcinoma and glioblastoma
  • Conducting Investigative Clinical Trial for
    Pancreatic Cancer
  • Completed Non-clinical studies for 6 cancer types
    (Lung cancer,
    Stomach cancer, Kidney cancer, Prostate cancer,
    Cervical cancer, Melanoma)
CAR-T Cell therapeutics
Autologous / Allogeneic CAR-CIK